Please login to the form below

Not currently logged in
Email:
Password:

rosuvastatin calcium

This page shows the latest rosuvastatin calcium news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca settles with generic rivals in Crestor patent challenge

AstraZeneca settles with generic rivals in Crestor patent challenge

The company said it has entered into a settlement agreement with Actavis and Egis Pharmaceuticals over their plan to launch generic Crestor (rosuvastatin calcium), blocking competition for the product until May ... Actavis (formerly Watson Pharma) filed

Latest news

  • Crestor can't top Lipitor in head-to-head study

    A study comparing the effects of AstraZeneca's Crestor (rosuvastatin calcium) with Pfizer's Lipitor (atorvastatin calcium) in has found no difference between the statin drugs in preventing the progression of ... The SATURN trial was designed to look at

  • AZ's Q3 income up as sales stay flat

    The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort

  • AstraZeneca partners with cooking website

    AstraZeneca (AZ) has entered into a partnership with Food University, a web-based culinary platform, to help educate consumers about healthy eating in support of the company's medication Crestor (rosuvastatin ... calcium), which is approved to lower

  • AZ sees decrease in Q4 profit

    Revenue for the year remained flat at around $33bn. Well-performing drugs for the company included cholesterol product, Crestor (rosuvastatin calcium), with the drug seeing a revenue increase of 26 per

  • Generics and legal costs affect AZ profits

    The company reported double-digit sales growth for cholesterol drug Crestor (rosuvastatin calcium), for which AZ has filed a law suit against Watson Pharmaceuticals in an effort to block the company

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Evan Lippman joins Aileron Therapeutics Evan Lippman joins Aileron Therapeutics

    Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics